{
    "clinical_study": {
        "@rank": "23252", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks"
            }, 
            {
                "arm_group_label": "GCJBP Laennec Inj.", 
                "arm_group_type": "Experimental", 
                "description": "GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "GCJBP Laennec Injection contains a variety of cytokines derived from human placenta, amino\n      acids, peptides, nucleobases, and carbohydrates. This product is approved for improving\n      liver function. Also, it has been prescribed for lots of diseases such as menopausal\n      disorders, atopic dermatitis, skin cares as well as fatigue for long time. Although its\n      action mechanism and clinical effectiveness are not still clear, there are reports which say\n      a strong probability of its clinical effectiveness in the chronic fatigue patients.\n\n      This study aims to investigate the safety and efficacy of GCJBP Laennec Inj. (Human placenta\n      hydrolysate) in the chronic fatigue patients through a randomized controlled tial."
        }, 
        "brief_title": "Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Fatigue Syndrome", 
            "Idiopathic Chronic Fatigue"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatigue", 
                "Fatigue Syndrome, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient diagnosed with chronic fatigue syndrome or idiopathic chronic fatigue\n\n          -  Given written informed consent\n\n          -  Male or female aged between 20 and 65\n\n          -  Patient who can read and answer to written questionnaires\n\n          -  Patient who agrees to visit clinic for study drug injection 3 times per a week for 6\n             weeks\n\n        Exclusion Criteria:\n\n          -  Patient who has been administrated with any other investigational product for 28 days\n             prior to screening visit\n\n          -  Patient who is pregnant or childbearing potential female patient who does not consent\n             for contraception during the study\n\n          -  Patient who has a hypersensitivity provoked by study drug or others drived from\n             animals\n\n          -  Patient who has been received with any human placenta product for 6 months before\n             study participation\n\n          -  Abnormal liver function\n\n          -  Abnormal renal function\n\n          -  Back Depression Inventory (BDI) II is more than 29\n\n          -  Underlying disease/conditions, in the investigator's judgment, which will be unable\n             to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742013", 
            "org_study_id": "Laennec-IIT"
        }, 
        "intervention": [
            {
                "arm_group_label": "GCJBP Laennec Inj.", 
                "description": "Test drug", 
                "intervention_name": "GCJBP Laennec Inj.", 
                "intervention_type": "Drug", 
                "other_name": "Human placenta hydrolysate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline solution (NaCl 0.9%)"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic Fatigue", 
            "CFS", 
            "ICF", 
            "human placenta"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Kangbuk Samsung Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon-si", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Ajou University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue", 
        "overall_official": {
            "affiliation": "Kangbuk Samsung Hospital", 
            "last_name": "Ho Cheol Shin, M.D., Ph.d.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change of Fatigue Severity Scale (FSS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742013"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kangbuk Samsung Hospital", 
            "investigator_full_name": "Ho Cheol Shin, M.D., Ph.D.", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change per item of Fatigue Severity Scale (FSS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3, 6 and 9 weeks"
            }, 
            {
                "measure": "Rate of patients whose FSS decreased from 4 and more to less than 4", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3, 6 and 9 weeks"
            }, 
            {
                "measure": "Change of Visual Analogue Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 and 6 weeks"
            }, 
            {
                "measure": "Change of Multidimensional Fatigue Inventory (MFI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 and 6 weeks"
            }, 
            {
                "description": "GIS assessment after 6-week study treatment by investigator", 
                "measure": "Global Improvement Scale (GIS)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Change in the concentration of salivary cortisol", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }, 
            {
                "measure": "Change in the concentration of interleukin-6 and interleukin 1b", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }, 
            {
                "measure": "Heart Rate Variability (HRV) parameters at resting", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 weeks"
            }, 
            {
                "description": "Compliance rate of used study drugs to prescribed study drugs after 6-week treatment", 
                "measure": "Drug compliance", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "All adverse events reported for study duration of 9 weeks", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "9 weeks"
            }
        ], 
        "source": "Kangbuk Samsung Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ajou University School of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Green Cross Corporation", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Symyoo", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ho Cheol Shin, M.D., Ph.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}